Your search for lymphoma matches 590 pages

Showing 201 - 250


lymphoma

Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

leukemia
lymphoma

Michael Pfreundschuh, MD, on Treating Lymphoid Malignancies in Children and Adults With the Same Protocols

Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.

survivorship
lymphoma

Erin Elizabeth Hahn, PhD, MPH, on Hodgkin Lymphoma: Post-Treatment Services

Erin Elizabeth Hahn, PhD, MPH, of Kaiser Permanente Southern California, discusses the use of recommended post-treatment services for adolescent and young adult Hodgkin lymphoma survivors (Abstract 107).

lymphoma

Ibrutinib in Relapsed Mantle Cell Lymphoma

Treatment of mantle cell lymphoma continues to evolve, both in the front-line and relapsed settings. Key advances include better use of established agents, such as the incorporation of high-dose cytarabine into initial induction regimens and application of rituximab (Rituxan)...

lymphoma

Phase III Trial Shows Improved Progression-Free Survival With Ibrutinib vs Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma

In aphase III trial reported in The Lancet and at the recent American Society of Hematology Annual Meeting and Exposition, Martin Dreyling, MD, of the European Mantle Cell Lymphoma Network, and colleagues found that ibrutinib (Imbruvica) was associated with improved progression-free survival vs...

lymphoma

Winning the Battle at the Front Lines: Lenalidomide Plus Rituximab— A Promising Initial Treatment for Mantle Cell Lymphoma

Mantle cell lymphoma is a pernicious, incurable disease. Front-line therapies for this disease are not currently standardized; however, novel therapies for relapsed or refractory mantle cell lymphoma can ideally be translated into beneficial treatments for newly diagnosed patients, as clearly...

hematologic malignancies
lymphoma

Lenalidomide Plus Rituximab Highly Active in  Initial Treatment of Mantle Cell Lymphoma

In a phase II trial reported in The New England Journal of Medicine by Jia Ruan, MD, PhD, and colleagues, first-line treatment with the immunomodulatory agent lenalidomide (Revlimid) and the anti-CD20 antibody rituximab (Rituxan) followed by maintenance lenalidomide and rituximab produced a high...

hematologic malignancies
lymphoma

Two Inherited Genetic Variants Predict Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

In a genome-wide association study reported in Journal of Clinical Oncology, Hervé Ghesquieres, MD, PhD, of Centre Léon Bérard, Lyon, France, and colleagues identified two inherited genetic variants that were associated with poorer event-free and overall survival in patients with diffuse large...

hematologic malignancies
lymphoma

Could CAR-T Therapy Be Moving Into Lymphoma?

The use of T cells that are genetically engineered to express chimeric antigen receptor (CAR-T) has made headway as an approach to hematologic malignancies, with the best results achieved in leukemia. At the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, a preliminary...

hematologic malignancies
lymphoma

Swedish Study Indicates No Pregnancy-Related Increase in Risk of Relapse in Hodgkin Lymphoma

In a Swedish study reported in the Journal of Clinical Oncology, Weibull et al found that pregnancy did not appear to increase the risk of subsequent relapse in women with Hodgkin lymphoma in remission. Study Details The study included data from Swedish health-care registers and medical records...

lymphoma
survivorship
issues in oncology

Study Shows Inferior Outcomes for African American Pediatric Lymphoma Patients

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have published a study showing that African American pediatric patients with Hodgkin lymphoma have inferior overall survival compared with their white and Hispanic peers. The study, published ...

hematologic malignancies
lymphoma

Long-Term Trial Finds Similar Survival Rates With Several Chemotherapy Regimens for Advanced Hodgkin Lymphoma

In the long-term follow-up of the Italian HD2000 trial reported by Merli et al in the Journal of Clinical Oncology, no significant differences in overall or progression-free survival were observed after 10 years among patients with previously untreated advanced Hodgkin lymphoma receiving ABVD...

colorectal cancer
hepatobiliary cancer
lung cancer
lymphoma

Increased Cancer Mortality Rate Among Recipients of Solid-Organ Transplants

Solid-organ transplant recipients have a higher rate of cancer mortality than what is expected in the general population, according to a Canadian study by Acuna et al published in JAMA Oncology. Cancer mortality among transplant recipients was significantly elevated compared with data for the...

lymphoma
survivorship

Survivorship Symposium 2016: Study Finds That Less Than Half of Survivors of Hodgkin Lymphoma Received All Recommended Follow-up Care

According to the American Cancer Society’s 2014 Cancer Facts & Figures, Hodgkin lymphoma is diagnosed in about 800 adolescents and young adults each year. And while standard treatments for the cancer, including chemotherapy and radiation, are very effective in improving survival,...

Lymphoma

Important Briefs: Lymphoma Research on Improved Chemotherapy, Biomarker Associations, and Stem Cell Transplant Approaches

The 11th International Conference on Malignant Lymphoma was held June 15–18 in Lugano, Switzerland. More than 3,000 hematologists, clinical oncologists, pathologists, and researchers attended the meeting, which was first convened in 1981. Topics of discussion included lymphoma staging in the new...

Lymphoma

Intergroup Study Evaluates Outcomes of Elderly vs Younger Patients Treated for Advanced Hodgkin Lymphoma

The 11th International Conference on Malignant Lymphoma was held June 15–18 in Lugano, Switzerland. Topics of discussion included lymphoma staging in the new millennium, lymphoma and its microenvironment, and lymphoma cure vs control. The ASCO Post summarized several key presentations in the July...

Lymphoma

Combined Therapy Produces Good Outcomes in Primary Testicular Diffuse Large B-cell Lymphoma

Final results of an international phase II trial of first-line treatment for primary testicular diffuse large B-cell lymphoma show that using a combined treatment strategy including chemotherapy and central nervous system and testicular prophlaxis “was associated with a good outcome.” The results...

Lymphoma

ODAC Recommends Accelerated Approval for Brentuximab

Seattle Genetics, Inc, announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 10-0 to recommend that the agency grant accelerated approval of brentuximab vedotin (ADCETRIS) for the treatment of patients with Hodgkin lymphoma who relapse after autologous stem cell transplant...

Lymphoma
Global Cancer Care

Treating Cancer in Japan: A Conversation with Kensei Tobinai, MD

In this installment of Oncology Worldwide, internationally regarded lymphoma expert and cancer survivor, Kensei Tobinai, MD, Chief, National Cancer Center Hospital, Tokyo, sheds light on the Japanese oncology experience. Medical Education What was the medical school experience in Japan like? When...

Lymphoma

Important Benefit for Small Population Is a Major Milestone in Lymphoma

The approval of brentuximab vedotin (Adcetris) is a major milestone for the treatment of patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. It represents an excellent example of personalized cancer therapy. Patients are preselected based on a predictive biomarker that is...

Lymphoma

FDA Approves Brentuximab Vedotin in Two Lymphoma Indications

The antibody-drug conjugate brentuximab vedotin (Adcetris) was granted accelerated approval on August 19 for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin is the first new drug to be approved in Hodgkin lymphoma in more...

Lymphoma

Similar Outcomes Confirmed in Variety of Lymphoma Treatment Comparisons

Three abstracts reported at the Best of ASCO® meeting in Seattle provide guidance to hematologists when it comes to long-standing gray areas in lymphoma management, according to Oliver Press, MD, PhD, of the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle....

Hematologic Malignancies
Leukemia
Lymphoma
Multiple Myeloma

NCCN Meeting Addresses Issues in Hematologic Malignancies

The National Comprehensive Cancer Network (NCCN) 6th Annual Congress on Hematologic Malignancies, held recently in New York, included reviews of the management of hematologic diseases as well as discussions of outstanding issues in the field. The following is a synopsis of some of the important...

Lymphoma

How Should We Treat Nodular Lymphocyte-predominant Hodgkin Lymphoma?

At the 2011 Pan-Pacific Lymphoma Conference in Kauai, Hawaii, Andreas Engert, MD, Chairman of the German Hodgkin Lymphoma Study Group (GHSG) and Professor of Medicine at the University Hospital of Cologne, Germany, discussed the treatment of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL),...

Lymphoma

Intensified Chemotherapy with R-ACVBP Improves Survival in Younger Patients with Diffuse B-cell Lymphoma

Compared with standard R-CHOP (rituximab [Rituxan], doxorubicin, cyclophosphamide, vincristine, and prednisone), intensified immunochemotherapy with R-ACVBP (dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine [not available in U.S.], bleomycin, and prednisone) significantly improves ...

Lymphoma

Update on Novel Treatments for Peripheral T-cell Lymphoma

At the recent Pan-Pacific Lymphoma Conference in Kauai, Hawaii, Julie M. Vose, MD, from the University of Nebraska Medical Center, Omaha, discussed novel treatments for peripheral T-cell lymphoma (PTCL). PTCL is a heterogeneous group of aggressive T-cell/natural killer (NK) cell non-Hodgkin...

Lymphoma
Geriatric Oncology

Expert Point of View: Therapy for Hodgkin Lymphoma in the Elderly Remains Undefined

Elderly Hodgkin lymphoma, typically defined as affecting individuals ≥ 60 years of age, remains a disease for which no standard treatment recommendation exists. This population is underrepresented in clinical studies, and survival rates in older patients with Hodgkin lymphoma are significantly and ...

Lymphoma
Geriatric Oncology

Therapy for Hodgkin Lymphoma in the Elderly Remains Undefined

At the 2011 Pan-Pacific Lymphoma Conference held recently in Kauai, Hawaii, Andrew M. Evens, DO, MSc, Director of the Lymphoma Program at the University of Massachusetts Medical School in Worcester, discussed Hodgkin lymphoma in elderly patients. Event-free survival and overall survival rates in...

Lymphoma

Favorable Early-stage Hodgkin Lymphoma and HD.6: The Take-Home and Don’t–Take-Home Messages

The Canadian HD.6 randomized study in patients with nonbulky early-stage Hodgkin lymphoma is mostly of historic interest.1,2 It has little relevance to current treatment standards or questions, and the risk for its inappropriate interpretation is of great concern. Radical Radiation Approach Long...

Lymphoma

Expert Point of View: Improved Survival with Chemotherapy Alone in Limited-stage Hodgkin Lymphoma

A criticism of the HD.6 trial is that current radiation techniques are probably less toxic than subtotal nodal radiation therapy, which was used in this investigation. Responding to this in an accompanying editorial in The New England Journal of Medicine,1 David J. Straus, MD, of the lymphoma...

Lymphoma

Improved Survival with Chemotherapy Alone in Limited-stage Hodgkin Lymphoma

An important study suggests that radiotherapy may not be a necessary addition to chemotherapy in previously untreated patients with limited-stage Hodgkin lymphoma, sparing patients the risks of late radiation-induced cardiac effects and second cancers. These data were based on 12 years of follow-up ...

Lymphoma

New Anti-CD20 Monoclonal Antibody Studied in B-cell Non-Hodgkin Lymphoma

The new anti-CD20 monocolonal antibody obinutuzumab is being studied in the treatment of patients with relapsed CD20-positive indolent B-cell non-Hodgkin lymphoma. GAUSS is the first clinical trial to compare obinutuzumab head-to-head against rituximab (Rituxan) induction therapy. “In this first...

Lymphoma

Expert Point of View: Maintenance Rituximab vs Retreatment Rituximab in Patients with Low–Tumor-Burden Follicular Lymphoma

The findings of RESORT1 have tremendous implications, both clinically and economically, commented Andrew D. Zelenetz, MD, Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center, New York, in an interview. “The maintenance arm received rituximab [Rituxan] every 3 months...

Lymphoma

Maintenance Rituximab vs Retreatment Rituximab in Patients with Low–Tumor-Burden Follicular Lymphoma

For patients with low–tumor-burden follicular lymphoma treated upfront with rituximab (Rituxan), retreating upon disease progression was as effective as extended dosing, or maintenance therapy, in a randomized phase III study that compared the approaches.1 Given the excellent outcomes, lack of a...

Lymphoma

Expert Point of View: Post-CHOP Radioimmunotherapy Comparable to Rituximab Given along with CHOP in Previously Untreated Follicular Lymphoma

SWOG S0016, which compared treatment with CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, plus rituximab [Rituxan]) and CHOP-RIT (CHOP plus tositumomab/iodine-131 tositumomab [Bexxar]) in patients with follicular lymphoma, was one of the most important studies at the 2011 ASH...

Lymphoma

Post-CHOP Radioimmunotherapy Comparable to Rituximab Given along with CHOP in Previously Untreated Follicular Lymphoma

In patients with previously untreated follicular lymphoma, similar outcomes were achieved with CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, plus six doses of rituximab [Rituxan]) and CHOP-RIT (CHOP plus one dose of tositumomab/iodine-131 tositumomab [Bexxar]) in a phase III...

Hematologic Malignancies
Leukemia
Lymphoma

ASH 2011 Presentations Include Novel Agents and New Strategies in Leukemia, Lymphoma, and Myeloma

Attendees at the 53rd Annual Meeting of the American Society of Hematology (ASH), held recently in in San Diego, were able to choose from a wide range of interesting and important sessions exploring hematologic malignancies. In addition to The ASCO Post’s regular news coverage from the meeting,...

Lymphoma

New Data Guide Treatment for Rare Form of Hodgkin Lymphoma

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) accounts for approximately 5% of Hodgkin lymphoma cases. It is distinguished from classic Hodgkin lymphoma by a variety of clinical and pathologic features, including expression of B-cell associated antigens such as CD20. Given that the...

Breast Cancer
Kidney Cancer
Lung Cancer
Skin Cancer
Leukemia
Lymphoma
Issues in Oncology

NCCN Clinical Practice Guidelines: Important Updates for 2012

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have become the most widely used guidelines in oncology practice. The Guidelines cover 97% of all patients with cancer and are continually updated by expert panels. The 2012 Guidelines include some completely...

Lymphoma

Two Cycles of Chemotherapy plus Involved-field Radiation Improves Tumor Control in Early Unfavorable Disease

Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial concluded that intensified chemotherapy with two cycles of escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine [Matulane], and prednisone) followed by two cycles of ABVD (doxorubicin,...

Lymphoma

Panobinostat Produces Objective Responses in Patients Refractory to Autologous Transplant

Panobinostat produced objective responses in 27% and tumor reductions in 74% of 129 patients enrolled in “the largest, prospective, multicenter, international trial conducted in heavily pretreated patients” with Hodgkin lymphoma who relapsed or were refractory to autologous stem cell...

Lymphoma

Newest Indication for Rituximab as Maintenance Treatment in Non‑Hodgkin Lymphoma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication The CD20-directed monoclonal antibody rituximab...

Lymphoma

Crizotinib Yields Benefits in Aggressive Pediatric Tumors

The value of the targeted agent crizotinib (Xalkori) may not be restricted to the 5% of patients with non–small cell lung cancer who have abnormalities in the ALK gene. In a phase I study conducted by the ­Children’s Oncology Group consortium, crizotinib halted tumor growth and, in some cases,...

Lymphoma

Radiotherapy in Early-stage Hodgkin Lymphoma

The treatment of patients with Hodgkin lymphoma is one of the major success stories in medical oncology. Depending on clinical stage, clinical risk factors, and the treatment given, 60% to 90% of all patients can be cured of their malignancy long-term. Hodgkin lymphoma survivors represent one of...

Lymphoma

After Complete Response to Chemotherapy, IFRT Improves Event-free Survival in Hodgkin Lymphoma

Final data from the Children’s Cancer Group (CCG) trial evaluating low-dose involved-field radiation therapy (IFRT) for patients with Hodgkin lymphoma achieving a complete response after chemotherapy show that at a median follow-up of 7.7 years, IFRT produced a statistically significant improvement ...

Lymphoma

Multicenter Phase II Trial Supporting Approval of Brentuximab Vedotin in Anaplastic Large-cell Lymphoma

Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive T-cell lymphoma subtype characterized by uniform expression of CD30. Apart from low- to intermediate-risk patients with ALK-positive disease, patients with ALCL have a poor prognosis when treated with conventional, anthracycline-based...

Hematologic Malignancies
Lymphoma

German Study Finds Bendamustine Improves Progression-free Survival in Patients with Non-Hodgkin Lymphoma

Updated results of the StiL NHL1 study, presented at the 2012 ASCO Annual Meeting Plenary Session, showed that bendamustine plus rituximab (Rituxan) more than doubled the median progression-free survival, compared with the standard R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin,...

Breast Cancer
Lymphoma
Survivorship

ASCO Studies Point to Risks Associated with Treating Childhood Cancers

Risks associated with being a young cancer survivor were emphasized by two studies highlighted in press briefings at the 2012 ASCO Annual Meeting. Investigators from the Children’s Oncology Group (COG) reported that adolescents and young adults  treated for high-risk B-precursor acute lymphoblastic ...

Lymphoma

Children with Favorable-risk Disease and Complete Response to Chemotherapy Have High Survival Rates without Radiotherapy

Among children with favorable-risk Hodgkin lymphoma, those who achieved a complete response after two cycles of chemotherapy and received no radiotherapy had high rates of survival similar to those who had a less complete response to chemotherapy and received radiotherapy, according to a study in...

Lymphoma

Study Shows Routine CT Surveillance Overused in Pediatric Hodgkin Lymphoma

The value of routine CT surveillance monitoring of pediatric patients for recurrence of Hodgkin lymphoma has been unclear. A study of CT surveillance recently reported by Stephan D. Voss, MD, PhD, and colleagues from the Children’s Oncology Group (COG) in the Journal of Clinical Oncology showed...

Advertisement

Advertisement



Advertisement